Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

References

• Agnihotri SM, Vavia PR. (2009). Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 5:90–5
   PubMed Web of Science ®Google Scholar
• Aqil M, Ali A, Sultana Y, Parvez N. (2004). Matrix type transdermal drug delivery systems of metoprolol tartrate: skin toxicity and in vivo characterization. Ethiop Pharm J 22:27–35
   Google Scholar
• Beloqui A, Solinis MA, Gascon AR, et al. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 166:115–23
   PubMed Web of Science ®Google Scholar
• Bunag RD. (1973). Validation in awake rats of a tail cuff method for measuring systolic blood pressure. J Appl Physiol 34:279–82
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Shukla D, Jain A, et al. (2009). Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interface Sci 335:242–9
   PubMed Web of Science ®Google Scholar
• Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci 89:967–78
   PubMed Web of Science ®Google Scholar
• Chen DB, Yang TZ, Lu WL, Zhang Q. (2001). In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 49:1444–7
   PubMed Web of Science ®Google Scholar
• Dollery C. (1999). Therapeutics drugs. Edinburgh: Churchill Livingstone, 75–80
   Google Scholar
• Fundaro A, Cavalli R, Bargoni A, et al. (2000). Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 42:337–43
   PubMed Web of Science ®Google Scholar
• Gehr TWB, Tenero DM, Boyle DA, et al. (1999). The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 55:269–77
   PubMed Web of Science ®Google Scholar
• Higuchi T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145–9
   PubMed Web of Science ®Google Scholar
• Jia L, Zhang D, Li Z, et al. (2010). Nano-structured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 80:213–18
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97–109
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker EM, et al. (1983). Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 15:25–35
   Web of Science ®Google Scholar
• Kumar MNR. (2000). Nano and microparticles as controlled drug delivery devices. J Pharm Sci 3:234–58
   Web of Science ®Google Scholar
• Liu D, Liu Z, Wang L, et al. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85:262–9
   PubMed Web of Science ®Google Scholar
• Muller RH, Maassen S, Weyhers H, Mehnert W. (1996). Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 4:161–70
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 50:161–77
   PubMed Web of Science ®Google Scholar
• Muller RH, Petersen RD, Hommoss A, Pardeike J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–30
   PubMed Web of Science ®Google Scholar
• Nisharani S, Ranpise NS, Korabu SS, Ghodake VN. (2014). Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 116:81–7
   PubMed Web of Science ®Google Scholar
• O’Driscoll CM, Griffin BT. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility- the potential impact of lipid-based formulations. Adv Drug Deliv Rev 60:617–24
   PubMed Web of Science ®Google Scholar
• Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110–11
   PubMedGoogle Scholar
• Porter CJH, Charman WN. (2001). Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 50:61–80
   PubMed Web of Science ®Google Scholar
• Priyanka K, Sathali AA. (2012). Preparation and evaluation of montelukast sodium loaded solid lipid nanoparticles. J Young Pharm 4:129–37
   PubMedGoogle Scholar
• Raj R, Mongia P, Ram A, Jain NK. (2015). Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. DOI: 10.3109/21691401.2015.1036997
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Khandasami US, Ruttala H, Shanmugam S. (2012). Development of solid lipid nanoparticles enriched hydrogels for topical delivery of anti-fungal agent. Macromol Res 20:682–92
   Web of Science ®Google Scholar
• Ranpise NS, Korabu SS, Ghodake VN. (2014). Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 116:81–7
   PubMed Web of Science ®Google Scholar
• Rizwan M, Aqil M, Azeem A, et al. (2009). Study of the degradation kinetics of carvedilol by use of a validated stability-indicating LC method. Chromatographia 70:1283–6
   Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Cho HJ, et al. (2014). Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotechnol 14:4820–31
   PubMed Web of Science ®Google Scholar
• Tsukamoto T, Hironaka K, Fujisawa T, et al. (2013). Preparation of bromfenac-loaded liposomes modified with chitosan for ophthalmic drug delivery and evaluation of physicochemical properties and drug release profile. Asian J Pharm Sci 8:104–9
   Google Scholar
• Ubaidulla U, Reddy MVS, Ruckmani K, et al. (2007). Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSciTech 8:E1–8
   PubMed Web of Science ®Google Scholar
• Wen X, Tan F, Jing Z, Liu Z. (2004). Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J Pharm Biomed Anal 34:517–23
   PubMed Web of Science ®Google Scholar
• Xie S, Zhu L, Dong Z, et al. (2011). Preparation, characterization, and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces 83:382–7
   PubMed Web of Science ®Google Scholar
• Zhang L, Han L, Sun X, et al. (2012). The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia 83:678–89
   PubMed Web of Science ®Google Scholar
• Zhuang CY, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–85
   PubMed Web of Science ®Google Scholar